Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg-kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg-kg injectable enrofloxacin for the treatment of ActinobReportar como inadecuado




Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg-kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg-kg injectable enrofloxacin for the treatment of Actinob - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Porcine Health Management

, 3:10

First Online: 10 May 2017Received: 27 August 2016Accepted: 04 April 2017DOI: 10.1186-s40813-017-0057-2

Cite this article as: Grandemange, E., Perrin, PA., Cvejic, D. et al. Porc Health Manag 2017 3: 10. doi:10.1186-s40813-017-0057-2

Abstract

BackgroundAcute outbreaks of Actinobacillus pleuropneumoniae APP require rapid, effective, parenteral antimicrobial treatment. The efficacy and safety of a single, short-acting, high dose of marbofloxacin Forcyl® swine 160 mg-mL compared with 1 or 2 doses of 7.5 mg-kg enrofloxacin in APP outbreaks in European farms was studied.

MethodsA controlled, randomised block, blinded, multicentre, field study was conducted on four farms with acute respiratory disease associated with APP. Animals with clinical signs of respiratory disease were allocated similarly to intramuscular treatments of either a single dose 8 mg-kg marbofloxacin on day 0 or, 7.5 mg-kg enrofloxacin Baytril 1nject® on day 0 and again on day 2, if clinical signs had not improved.

ResultsThe results were similar for intention to treat 242 pigs and per protocol populations 239 pigs. On day 0, all pigs had pyrexia means, 40.6 °C, moderate to severe clinical signs depression, cough, dyspnoea. Following treatment, animals improved rapidly and on day 7, clinical signs were absent or mild in all pigs and mean temperatures for each treatment were <39.5 °C P > 0.05. The primary efficacy criterion, animals cured, for marbofloxacin and enrofloxacin was 81.8 and 81.4% on day 7, and 84.2 and 82.2% on day 21, respectively. Results for cure, respiratory disease removals and mortalities, and relapses were compared using confidence intervals and confirmed that marbofloxacin was non-inferior to enrofloxacin P > 0.05. There were no significant treatment differences in live weight gains, adverse events and injection site reactions <2.5% animals P > 0.05. Significantly more animals developed concurrent disorders in the enrofloxacin 7.5% than marbofloxacin 0.0% group P < 0.01. On day 0, the MIC90 values of APP for marbofloxacin and enrofloxacin were 0.06 μg-mL for APP, less than the clinical breakpoints.

ConclusionsMarbofloxacin single dose of 8 mg-kg and enrofloxacin 1 or 2 doses of 7.5 mg-kg were clinically safe and effective in the treatment of clinical respiratory disease associated predominantly with APP in four European commercial, fattening pig herds.

KeywordsMarbofloxacin Enrofloxacin Respiratory disease Efficacy Actinobacillus pleuropneumoniae Minimum inhibitory concentration AbbreviationsAPPActinobacillus pleuropneumoniae

BALBronchoalveolar lavage

CLSIClinical and Laboratory Standards Institute

CPControl product

IVPInvestigational veterinary product

MIC50MIC90, lowest concentrations μg-mL of the antimicrobial for which 50 and 90% of the isolates were inhibited, respectively

MPCMutant prevention concentration

PDPharmacodynamics

PKPharmacokinetics

PMPasteurella multocida

SRDSwine respiratory disease





Autor: Erik Grandemange - Pierre-Alexandre Perrin - Dejean Cvejic - Miriam Haas - Tim Rowan - Klaus Hellmann

Fuente: https://link.springer.com/







Documentos relacionados